This page lists the opinions adopted at the December 2011 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes.
The new format allows users to view the main opinions adopted at the meeting, along with information on referral procedures, in a clear tabular format. Users can click on the links within the page to read individual press releases and more detailed information about the opinions.
The new format replaces the two PDF documents that used to list each meeting's outcome: the CHMP meeting highlights, published on the Friday following the meeting and the CHMP monthly report, published around a week later. The Agency will publish a new page following each month's CHMP meeting.
The Agency is gathering feedback from journalists and other stakeholders over the first three months of publication. It will make any necessary changes to the format in early 2012.
Positive opinions on new medicines
Name of medicine | INN | Marketing authorisation applicant |
---|---|---|
CHMP summary of positive opinion for Esmya | ulipristal | PregLem France SAS |
CHMP summary of positive opinion for Vepacel | A/H5N1 pre-pandemic influenza vaccine (whole virion, vero cell derived, inactivated) | Baxter Innovations GmbH |
CHMP summary of positive opinion for Zelboraf
| vemurafenib | Roche Registration Ltd |
Positive opinions on extensions of therapeutic indications
Name of medicine | INN | Marketing authorisation holder |
---|---|---|
CHMP post-authorisation summary of positive opinion for GalvusCHMP post-authorisation summary of positive opinion for JalraCHMP post-authorisation summary of positive opinion for Xiliarx | vildagliptin | Novartis Europharm Ltd |
CHMP post-authorisation positive summary of opinion for ProcoralanCHMP post-authorisation positive summary of opinion for Corlentor | ivabradine | Les Laboratoires Servier |
Positive opinion on other changes to the marketing authorisation
Name of medicine | INN | Marketing authorisation holder |
---|---|---|
Vimpat | lacosamide | UCB Pharma SA |
Final opinion on safety reviews for centrally and non-centrally authorised medicines
Final opinion on arbitration procedure
Name of medicine | INN |
---|---|
Norditropin | somatropin |